Biomaterials Science Submission Guide

Source: Biomaterials Science author guidelines.

Use this page when deciding:

• whether the biomaterials contribution is substantive

• whether biological characterization is rigorous

• whether biomaterials framing is articulated

• a clear biomaterials contribution

• rigorous biological characterization

• biomaterials framing

• material-property linkage

• a cover letter establishing the contribution

• Descriptive biomaterials studies without application.

• Weak biological characterization.

• Missing biomaterials framing.

• General materials research without biomaterials focus.

Biomaterials Science is a flagship biomaterials journal.

Biomaterials-application standard: the journal differentiates from broader materials venues by demanding biomaterials contributions.

Biological-characterization expectation: editors expect in vitro or in vivo validation.

The initial editorial assessment: decisive editorial screen (RSC publishes no desk-rejection rate for the journal).

The strongest Biomaterials Science editor-facing notes establish:

• the biomaterials contribution

• the biological characterization

• the biomaterials framing

• the central finding

A Biomaterials Science submission involves these items; RSC asks for some of them only at the revision stage or after acceptance:

• main manuscript file as Word, PDF or LaTeX (the RSC template is optional)

• cover letter establishing the biomaterials advance and biological-application relevance

• table of contents entry (a graphic plus 1-2 sentences of up to 250 characters summarising the biomaterials advance), which RSC asks for at the revision stage

• ORCID iD for the submitting author (RSC requires it when a revised manuscript is submitted and encourages all co-authors to link theirs)

• conflicts of interest statement (RSC requires one for every submitted manuscript; if none exist, it reads "There are no conflicts to declare")

• ethical statement where the study involves live animals or human subjects (RSC's author guidelines say one may be required; its author responsibilities page requires a methods-section statement naming the ethics committee that approved the study and, where possible, the approval or case number)

• data availability statement covering material synthesis data, cell-culture data, in vivo data, and any imaging or characterization datasets

• supporting information (compiled separately; RSC peer-reviews it, so include it with the original submission)

• for Communications, a brief paragraph in the cover letter justifying the importance and urgency that warrants the rapid-publication track

• for Review proposals, a completed Review Proposal Form assessed by the Editor-in-Chief; approved proposals receive a personalized submission link

• declaration of any generative AI use in the cover letter (RSC also asks for a statement in the methods section and the tool details in the Acknowledgements)

• for revised submissions, a response to the referees, figures as separate high-resolution files and a table of contents entry

For Biomaterials Science submissions, the most common artifact-related issue is missing or weak biological-characterization data on materials-focused submissions. The journal title is "Biomaterials Science" rather than "Biomaterials Engineering"; RSC's scope statement says papers should provide novel insight into the biological applications of the biomaterial, so the biology belongs in the package at first submission, not promised as future work. RSC adds that articles primarily focused on demonstrating novel materials chemistry are more suited to its companion journal, Journal of Materials Chemistry B.

Biomaterials Science manuscripts move through the stages RSC describes for its journals. RSC's journal page gives a median time to first decision of 10 days for all first decisions, including rejections without peer review, and 33 days for submissions that were peer reviewed (RSC figures for 2025); RSC publishes no stage-by-stage timetable.

Submission and completeness check

After submission, RSC checks the files for completeness and the editorial team contacts the submitting author if something is missing. The manuscript is then assigned to a publishing editor at RSC or to an associate editor. For Communications, RSC asks authors to indicate briefly in a covering letter why publication as a Communication is justified.

Initial assessment by an editor

An editor assesses whether the manuscript is suitable for peer review, looking at scope, scientific quality, general interest and novelty. RSC's scope statement says papers do not necessarily need to report a new biomaterial but should provide novel insight into the biological applications of the biomaterial, and that articles primarily focused on novel materials chemistry are more suited to Journal of Materials Chemistry B. RSC says a manuscript may be returned without external review, or the authors may be offered a transfer to another RSC journal.

External peer review

Manuscripts that pass the initial assessment are peer reviewed by independent experts in the relevant field. RSC's Biomaterials Science page does not state how many reviewers are used. RSC's manuscript tracker shows the number of reviewers who have agreed to provide a report.

Decision and revision

The handling editor makes the decision on the basis of the reviewer reports. For a revision, RSC asks for a response to the referees, figures as separate high-resolution files and a table of contents entry. RSC publishes no figure for the number of revision rounds.

• Is Biomaterials Science a good journal?

• Acta Biomaterialia Submission Guide for biomaterials manuscripts where the biological response, tissue interaction, or in vivo validation package needs a higher-selectivity biomaterials venue.

Before upload, run your manuscript through a Biomaterials Science check.

Mechanics are documented above. The reviewability of the draft is not. The review tells you whether your paper clears the Biomaterials Science fit check before upload, especially around descriptive biomaterials studies without application, weak biological characterization, and missing biomaterials framing. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.

Across biomaterials manuscripts targeting Biomaterials Science, three recurring patterns explain the majority of desk rejections.

In our pre-submission review work, we see many Biomaterials Science desk rejections trace to descriptive biomaterials studies. We also often find these cases involve weak biological characterization. A related pattern is that these cases often arise from missing biomaterials framing.

Descriptive biomaterials studies without application

Editors look for biological-application advances. We observe submissions framed as material descriptions routinely desk-rejected.

Check descriptive biomaterials studies without application before submitting to Biomaterials Science →

Weak biological characterization

Editors expect in vitro or in vivo validation. We see manuscripts with thin biological data routinely returned.

Check weak biological characterization before submitting to Biomaterials Science →

Missing biomaterials framing

Biomaterials Science specifically expects biomaterials focus. We find papers framed as general materials without biomaterials positioning routinely declined. A Biomaterials Science check can identify whether the package supports a submission.

Clarivate 2026 JCR release bibliometric data places Biomaterials Science among top biomaterials journals.

Check missing biomaterials framing before submitting to Biomaterials Science →

This page was researched from Biomaterials Science's author guidelines, RSC editorial-policy materials, Clarivate JCR data, and our pre-submission review work on submissions. The publicly verifiable facts (metrics, article types, submission portal, and editorial timeline) come from RSC and Clarivate sources; the pre-submission patterns come from our own review work. We have not personally been Biomaterials Science authors, so the editorial-behavior claims describe publicly documented scope rather than insider knowledge.

In pre-submission diagnostic work for top biomaterials journals, we consistently see four signals that distinguish strong submissions from weak ones. First, the contribution must be application-oriented. Second, biological characterization should be rigorous. Third, biomaterials framing should be primary. Fourth, material-property linkage should be established.

For Biomaterials Science-targeted manuscripts, the single most consistent feedback class we deliver in pre-submission diagnostics for Biomaterials Science is the descriptive-versus-application distinction. Editors expect application contributions. Submissions framed as "we synthesized material X" without biological application routinely receive "where is the application?" feedback. We coach authors to lead with the application question.

For Biomaterials Science-targeted manuscripts, beyond the rubric checks, three pre-submission diagnostic patterns recur most often in the manuscripts we review for Biomaterials Science. First, manuscripts where the abstract reports synthesis without biological characterization are flagged. Second, manuscripts where biological assays lack controls are flagged. Third, manuscripts that lack engagement with Biomaterials Science's recent issues are flagged.

The Biomaterials Science submissions we coach toward acceptance distinguish themselves on three operational behaviors. First, the cover letter names a translational endpoint (clinical indication, regulatory pathway, or named patient population) within the first 80 words rather than ending vaguely on "biomedical applications." Second, the figure layout reserves one of the early main-text figures (often Figure 2) for the biological-functional result rather than placing all biology in the supplementary.

Third, the discussion explicitly compares the new biomaterial to at least two recent Biomaterials Science papers that addressed the same clinical problem from different chemistries.

Editorial triage at Biomaterials Science is an initial assessment by an editor; RSC says only manuscripts that pass it are forwarded to reviewers. We coach researchers to design abstract, introduction, and conclusions for fast assessment.

Beyond methodology and contribution, RSC asks its editors and reviewers to focus on the science instead of the names, locations or career stages of the authors. Strong submissions reference Biomaterials Science's recent papers explicitly and position the new work against the specific design tension those papers left open.

The cover letter is the clearest place to set this frame. Name the biomaterials advance and its biological-application relevance in the first paragraph, then point the editor to where the biological-functional result appears in the main text. A frame that reads as a continuation of an ongoing journal conversation, rather than an isolated synthesis result, gives the desk editor a faster reason to send the manuscript to review.

For Biomaterials Science-targeted manuscripts, beyond methodology and contribution, journals at this tier increasingly reward submissions that explicitly position the work within a specific subfield conversation rather than treating the literature as undifferentiated.

For Biomaterials Science specifically, three desk-rejection patterns recur in our pre-submission reviews. First, materials-only papers with deferred biology ("biological evaluation underway, will be added at revision") are treated as out-of-scope rather than as work-in-progress. Second, in vivo claims supported by a single small-animal cohort without sample-size justification fail the editorial-rigor check. Third, biomaterial-device papers that do not engage with the FDA / EMA regulatory pathway in the discussion are flagged as incomplete for a journal that emphasizes translation toward clinical use.

Before any Biomaterials Science submission, we walk authors through a journal-specific pre-flight checklist that mirrors what the Editor and reviewers will actually look for:

• the cover letter names a clinical or translational endpoint within the first paragraph

• the abstract reports at least one biological-functional outcome alongside the materials characterization

• in vitro evidence uses a cell line or primary cell type relevant to the claimed application (not just NIH/3T3 or HeLa unless the indication justifies it)

• any in vivo data uses sample sizes justified by a power calculation

• the discussion engages the FDA or EMA regulatory pathway if the work claims translational relevance

• the recent-literature engagement section names at least three Biomaterials Science papers from the past 24 months on the same target indication